Compare OGN & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | MGNI |
|---|---|---|
| Founded | 1923 | 2007 |
| Country | United States | United States |
| Employees | N/A | 514 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2020 | 2014 |
| Metric | OGN | MGNI |
|---|---|---|
| Price | $9.69 | $13.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $11.75 | ★ $25.22 |
| AVG Volume (30 Days) | ★ 6.4M | 1.7M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | N/A | ★ 493.75 |
| EPS | 0.72 | ★ 0.95 |
| Revenue | ★ $6,216,000,000.00 | $156,414,000.00 |
| Revenue This Year | $0.45 | $6.28 |
| Revenue Next Year | $1.67 | $9.76 |
| P/E Ratio | ★ $12.94 | $14.34 |
| Revenue Growth | N/A | ★ 25.45 |
| 52 Week Low | $5.69 | $10.63 |
| 52 Week High | $13.25 | $26.65 |
| Indicator | OGN | MGNI |
|---|---|---|
| Relative Strength Index (RSI) | 76.35 | 66.41 |
| Support Level | $8.63 | $13.44 |
| Resistance Level | $10.10 | $14.48 |
| Average True Range (ATR) | 0.58 | 0.54 |
| MACD | 0.42 | 0.24 |
| Stochastic Oscillator | 96.66 | 87.09 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.